You are here

AusPAR: Ixekizumab

Related information


How to access a pdf or Word document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Australian Public Assessment Report

6 July 2020
AusPAR Details
AusPAR
Active Ingredient
Ixekizumab
Product Name
Taltz
Sponsor
Eli Lilly Australia Pty Ltd
Submission Number
PM-2018-05753-1-3
Submission Type
Extension of indications
Decision
Approved
AusPAR Date
22 June 2020
Publication Date

6 July 2020